Login / Signup

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study.

Arschang ValipourSergey N AvdeevAdam BarczykValentina BayerZvi G FridlenderMariela GeorgievaOndřej KudelaAlexey MedvedchikovRamona MironMaria SanzharovskayaVirginija ŠileikienėJurij ŠorliMarc SpielmannsZsuzsanna Szalai
Published in: International journal of chronic obstructive pulmonary disease (2021)
In 4700 COPD patients, 6 weeks' treatment with tiotropium/olodaterol, as initial treatment or follow-up to LAMA or LABA monotherapy or LABA/ICS, improved CCQ and decreased rescue medication use. The adverse event profile was consistent with the known safety profile of tiotropium/olodaterol.
Keyphrases
  • clinical practice
  • chronic obstructive pulmonary disease
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • randomized controlled trial
  • replacement therapy
  • air pollution
  • preterm birth
  • adverse drug